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ORIGINAL INVESTIGATIONS
Ambulatory Hemodynamic Monitoring
Reduces Heart Failure Hospitalizations in
“Real-World” Clinical Practice
Akshay S. Desai, MD, MPH,a Arvind Bhimaraj, MD, MPH,b Rupinder Bharmi, MS,c Rita Jermyn, MD,d
Kunjan Bhatt, MD,e David Shavelle, MD,f Margaret M. Redﬁeld, MD,g Robert Hull, MD,h Jamie Pelzel, MD,i
Kevin Davis, BS,c Nirav Dalal, MS, MBA,c Philip B. Adamson, MD,c J. Thomas Heywood, MDj
ABSTRACT
BACKGROUND In the CHAMPION (CardioMEMSHeart Sensor AllowsMonitoring of Pressure to ImproveOutcomes inNew
YorkHeart Association [NYHA] Functional Class III Heart Failure Patients) trial, heart failure hospitalization (HFH) rateswere
lower in patients managed with guidance from an implantable pulmonary artery pressure sensor compared with usual care.
OBJECTIVES This study examined the effectiveness of ambulatory hemodynamic monitoring in reducing HFH outside
of the clinical trial setting.
METHODS We conducted a retrospective cohort study using U.S. Medicare claims data from patients undergoing
pulmonary artery pressure sensor implantation between June 1, 2014, and December 31, 2015. Rates of HFH during
pre-deﬁned periods before and after implantation were compared using the Andersen-Gill extension to the Cox
proportional hazards model while accounting for the competing risk of death, ventricular assist device implantation,
or cardiac transplantation. Comprehensive heart failure (HF)–related costs were compared over the same periods.
RESULTS Among 1,114 patients receiving implants, there were 1,020 HFHs in the 6 months before, compared with
381 HFHs, 139 deaths, and 17 ventricular assist device implantations and/or transplants in the 6 months after implantation
(hazard ratio [HR]: 0.55; 95% conﬁdence interval [CI]: 0.49 to 0.61; p<0.001). This lower rate of HFHwas associated with
a 6-month comprehensive HF cost reduction of $7,433 per patient (IQR: $7,000 to $7,884), and was robust in analyses
restricted to 6-month survivors. Similar reductions in HFH and costswere noted in the subset of 480patientswith complete
data available for 12 months before and after implantation (HR: 0.66; 95% CI: 0.57 to 0.76; p < 0.001).
CONCLUSIONS As in clinical trials, use of ambulatory hemodynamic monitoring in clinical practice is associated with
lower HFH and comprehensive HF costs. These beneﬁts are sustained to 1 year and support the “real-world” effec-
tiveness of this approach to HF management. (J Am Coll Cardiol 2017;69:2357–65) © 2017 by the American College of
Cardiology Foundation.
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D espite considerable progress in thedevelopment of effective medicaltherapy, patients with chronic
heart failure (HF) remain at high risk for
recurrent hospitalization and death (1). In
the Medicare-eligible population, roughly
1 in 4 patients are readmitted within 30
days of hospitalization, and nearly one-half
are readmitted within 6 months (2). Most of
these hospitalizations are related to conges-
tive exacerbations driven by a progressive
rise in intracardiac ﬁlling pressures, independent of
ejection fraction or etiology (3–7).
Data from trials of implantable hemodynamic
monitoring demonstrate that inmany (although not all)
cases, ﬁlling pressures rise weeks in advance of symp-
toms sufﬁcient to trigger clinical attention, suggesting a
window of opportunity to intervene to prevent heart
failure hospitalizations (HFHs) with early detection of
congestion (8). Although several methods for remote
monitoring of HF patients have been considered, ap-
proaches that focus on weight (9–11) and changes in
device-based diagnostics (such as intrathoracic
impedance [12]) have not been effective in reducing
hospitalization rates. In contrast, HF management
guided by longitudinal access to pulmonary artery
pressures (PAPs) was associated with substantial
reduction in rates of HFH in the CHAMPION (Car-
dioMEMS Heart Sensor Allows Monitoring of Pressure
to Improve Outcomes in New York Heart Association
[NYHA] functional Class III Heart Failure Patients) trial.
These beneﬁts persisted over the full duration of ran-
domized follow-up (13), were consistent in patients
with both preserved and reduced ejection fraction (14)
as well as Medicare-eligible subjects (15), and were
tightly linked to the achieved reduction in PAP with
diuretic agents and other guideline-directed pharma-
cological therapies (16). Based on these observations, in
May 2014, the U.S. Food andDrug Administration (FDA)
approved the CardioMEMS HF System (Abbott, Sylmar,
California) as an approach to reducing HFH in patients
with chronicHF,NewYorkHeart Association functional
class III functional capacity, and a hospitalization for
HF management in the year prior to implantation.
Therapeutic efﬁcacy of an intervention in select
populations managed within the tightly regulated
framework of a clinical trial may not accurately
represent real-world effectiveness during general
use in clinical practice. The early experience of
hemodynamic-guided HF management does suggest
that the PAP reductions achieved with hemodynamic
monitoring in the “real world” are comparable to those
observed during the CHAMPION trial (17). It remains
unclear, however, whether these pressure reductions
have meaningfully inﬂuenced the rate of HFH in
implanted patients. We examined publicly available
administrative claims data from the U.S. Centers for
Medicare & Medicaid Services (CMS) to compare the
rates of HFH and the costs associated with HF care in
the periods before and after PAP sensor implantation.
METHODS
DATA SOURCE AND IDENTIFICATION OF THE
COHORT. We conducted a retrospective cohort study
using CMS administrative claims data from the Stan-
dard Analytic File to evaluate health care utilization in
U.S. fee-for-service Medicare beneﬁciaries receiving a
PAP sensor implant during the period following FDA
approval for commercial use (from June 1, 2014, on-
ward). These data include Part A inpatient claims, Part
B outpatient claims, and the associated denominator
ﬁles (18). The inpatient and outpatient ﬁles contain
institutional claims with International Classiﬁcation
of Diseases-Ninth or -Tenth Revision-Clinical Modiﬁ-
cation diagnosis codes, procedure codes, and reim-
bursement associated with inpatient stays or
ambulatory visits. The denominator ﬁles include
unique deidentiﬁed patient identiﬁcations, age, sex,
geographic location, race or ethnicity, date of death (if
present), and information about program eligibility
and Medicare insurance enrollment.
PAP sensor implants were identiﬁed by inpatient
claims associated with the procedure codes 38.26,
02HQ30Z, or 02HR30Z and outpatient claims associ-
ated with Current Procedural Terminology codes
C9741 and C2624 (Online Table 1). As Medicare data
were available through June 30, 2016, only implants on
or before December 31, 2015, were included to ensure a
minimum of 6 months of potential follow-up. The
cohort was further limited to patients with contin-
uous, fee-for-service (non–health maintenance orga-
nization) Medicare insurance enrollment (Parts A and
B) for at least 6 months before and after implantation,
retaining those who died at any time post-implant
(6-month cohort). A subset of patients who received
SEE PAGE 2366
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and Medicaid Services
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hospitalization
PAP = pulmonary artery
pressure
VAD = ventricular assist device
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implants before June 30, 2015, with continuous
Medicare enrollment and follow-up data available for
12 months before and after device implantation were
considered in a separate analysis (12-month cohort).
The analysis plan was jointly conceived by the prin-
cipal author (A.S.D.) in partnership with the sponsor,
with all statistical analyses performed by the out-
comes research group (R.B., K.D., and N.D.) at Abbott
(Sylmar, California). The claims data were extracted
using Apache Spark version 2.0.1 (Apache Software
Foundation, Forest Hill, Maryland) with Python
version 3.5.2 (Python Software Foundation, Beaver-
ton, Oregon), and the statistical analyses were con-
ducted using Revolution R version 3.1.1. (Revolution
Analytics, Mountain View, California). An indepen-
dent review of the results was conducted by external
health care economic consultants before publication.
The paper was drafted by the principal author (A.S.D.),
with input from all coauthors.
ANALYSIS OF EFFECTIVENESS. We compared rates
of HFH (deﬁned using the published CMS methodol-
ogy [19]) and all-cause hospitalization during the
6 months before and following device implantation
using the Andersen-Gill model for recurrent events,
with censoring at the time of death, ventricular
assist device (VAD) implantation, or cardiac trans-
plantation. For the subset of patients with available
data, we separately analyzed the same hospitalization
rates during the 12months before and following device
implantation. Heart transplant or VAD implantation
was identiﬁed using a Medicare severity diagnosis
related groups assignment of 001 or 002 (heart trans-
plant or implant of heart assist system without major
comorbidity or complication). For all analyses, event
accumulation was analyzed forward and backward
from the date of PAP sensor implant. A robust variance
estimate (20) was used in the Andersen-Gill model to
account for possible within-participant dependence.
ANALYSIS OF COSTS. As HFH is a principal driver of
health care costs, we simultaneously conducted a
comparison of the comprehensive (inpatient and
outpatient) costs associated with HF care during the
periods before and after implantation. For patients
implanted in an outpatient setting, the health care
encounter containing the relevant Current Procedural
Terminology code was deﬁned as the implant
encounter, with events before and after this encounter
attributed to the pre- and post-implant periods,
respectively. For patients who had a PAP sensor
implanted in an inpatient setting, the associated hos-
pitalization and any preceding events were counted
toward the pre-implant period, whereas any encounters
after hospital discharge were counted toward the
post-implant period. Classiﬁcation of an encounter as
being HF-related or not was made on the basis of the
presence of an HF code (Online Table 2) in the primary
diagnosis code position, as per the published CMS
methodology (19). The principal cost comparison was
between the 6 months before and after implantation,
but analyses were repeated for the cohort of patients
with 12-month (pre/post) data available. A nonpara-
metric bootstrapmethod (21,22) was used for comparing
the pre- and post-implant costs (Online Appendix).
SENSITIVITY AND SUBGROUP ANALYSES. Because some
implants occurred in themidst of anHFhospitalization,
sensitivity analyses restricted to outpatient implants
were performed to assess consistency of the results. To
further address possible confounding of the analyses by
the competing risk of death, we repeated analyses in
cohorts restricted to patients who survived the full
analytic interval (6 or 12 months). Results in subgroups
deﬁned by sex and age $75 years were also analyzed
due to concerns previously raised regarding differential
efﬁcacy of hemodynamic monitoring in these groups.
Additional sensitivity analyses, consisting of general-
ized estimating equations (GEE) models using both
Poisson and negative binomial models, further sup-
ported the ﬁndings.
RESULTS
Of 1,935 Medicare patients who underwent a PAP
sensor implantation from June 1, 2014, to December 31,
2015, there were 1,114 who were continuously enrolled
and had available data regarding health care utiliza-
tion for at least 6 months before and after implanta-
tion, and 480 who had complete data for 12 months
before and after implantation (see Figure 1 for details
of patient selection). For the 6-month cohort, the ma-
jority of PAP sensor implants (n¼ 832; 74.7%) occurred
in the ambulatory setting, rather than during an HF
hospitalization. Among patients who underwent PAP
sensor implantation in the outpatient setting, the
average time from the most recent HFH to device im-
plantation was 63.2  47.5 days. Selected patient
characteristics at the time of sensor implantation for
the 6- and 12-month cohorts are summarized in Table 1.
Overall, for both cohorts, the mean age was 71  11
years, with 40% of subjects at least 75 years of age, 36%
women, 14% black race, and a large burden of comor-
bid medical illness, including diabetes, hypertension,
and chronic obstructive pulmonary disease.
Clinical outcomes for the 6 months before and after
implantation are summarized in Table 2. For the
entire cohort, there were 1,899 all-cause hospitaliza-
tions and 1,020 HFHs in the 6 months before
implantation, compared with 1,119 all-cause
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hospitalizations, 381 HFHs, 17 VAD implantations or
transplants, and 139 deaths in the 6 months after
device implantation. A total of 81% of patients were
hospitalized at least once for any cause in the
6 months before device implantation, compared with
50% of patients in the 6 months after implant.
Further, 59% of patients had at least 1 HFH pre-
implant, compared with 22% of patients during the
6 months post-implant. The median number of HFHs
per patient was 0.92 at 6 months before and 0.37 at 6
months after device implantation. As shown in the
Central Illustration, Panel A, the cumulative incidence
of HFH was signiﬁcantly lower in the period following
device implantation (hazard ratio [HR]: 0.55; 95%
conﬁdence interval [CI]: 0.49 to 0.61; p < 0.001).
This observation was consistent in analyses
restricted to 6-month survivors (excluding those with
post-implant death, VAD, or transplant), in subgroups
deﬁned by sex and age $75 years, across all Medicare
administrative contractors, and in analyses restricted
to outpatient implants (Figure 2, Online Figure 1).
Additional sensitivity analyses using both a Poisson
GEE model and negative binomial regression GEE
model were performed, which further supported the
robustness of the results. For the Poisson model, the
incidence rate ratio was 0.60 (95% CI: 0.53 to 0.68),
and for the negative binomial regression models it
was 0.64 (95% CI: 0.57 to 0.73).
Reductions in HFH were associated with an esti-
mated reduction in costs related to HF care of $7,433/
patient in the 6 months following implantation rela-
tive to the period before implantation (IQR: $7,000
to $7,884/patient at 6 months before implantation;
p < 0.001). All-cause hospitalizations were also
reduced in the post-implant interval (HR: 0.69; 95%
CI: 0.64 to 0.75; p < 0.001), with associated reduction
in total health care costs (Table 2).
Clinical outcomes for the subset of patients with
complete 12-month data available for the period
before and after implantation are summarized in
Table 2. For these 480 subjects, there were 1,387
all-cause hospitalizations and 696 HFHs in the
12 months before implantation, compared with 859
all-cause hospitalizations, 300 HFHs, 15 VAD
implantations or transplants, and 106 deaths after
device implantation. As observed at 6 months, rela-
tive to the pre-implant interval, the cumulative
incidence of HFH was also signiﬁcantly lower in the
FIGURE 1 Flow Diagram of Patient Selection
694 implanted after Jan 1, 2016
1,241 with minimum 6-month
follow-up data available
127 not continuously enrolled
 in Medicare Part A and B or
enrolled in HMO insurance
556 implanted after June 30, 2015
78 not continuously enrolled
in Medicare Part A and B; or
enrolled into HMO insurance
1114
6-month cohort (Primary analysis)
558 with minimum 12-month
follow-up data available
480
1 year cohort (Secondary analysis)
1,935 patients with PAP
 sensor implants from
 June 1, 2014-June 30, 2016
Shown are the criteria used to select the 6- and 12-month cohorts for analysis from the
total number of identiﬁed PAP sensor implants in the Medicare cohort during the period
from June 1, 2014 to June 30, 2016. HMO ¼ health maintenance organization;
PAP ¼ pulmonary artery pressure.
TABLE 1 Patient Characteristics (on the Basis of Medicare Claims
Data) at the Time of PAP Sensor Implantation for Cohorts With
6- and 12-Month Data Available
6-Month Cohort
(n ¼ 1,114)
12-Month Cohort
(n ¼ 480)
Age, yrs 71.3  10.8 71.4  11.4
Age $75 yrs 460 (41.3) 211 (44.0)
Female 403 (36.2) 180 (37.5)
Race
White 902 (81.0) 396 (82.5)
Black 161 (14.5) 69 (14.4)
Other 51 (4.6) 15 (3.1)
Comorbidities*
Diabetes 727 (65.3) 311 (64.8)
Hypertension 1,089 (97.8) 471 (98.1)
COPD 861 (77.3) 384 (80.0)
Values are mean  SD or n (%). *Comorbidities identiﬁed using diagnosis codes
from health care encounters in the 6 months before implant.
COPD¼ chronic obstructive pulmonary disease; PAP¼ pulmonary artery pressure.
Desai et al. J A C C V O L . 6 9 , N O . 1 9 , 2 0 1 7
HFH Reductions With PAP Monitoring M A Y 1 6 , 2 0 1 7 : 2 3 5 7 – 6 5
2360
Downloaded for Anonymous User (n/a) at CentraCare Health from ClinicalKey.com by Elsevier on October 30, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
12-month period following device implantation
(HR: 0.66; 95% CI: 0.57 to 0.76; p < 0.001) (Central
Illustration, Panel B). Observed reductions in compre-
hensive HF costs relative to the pre-implant period
were estimated at $11,260 per patient-year (IQR:
$10,460 to $12,020 per patient-year; p < 0.001).
The reduction in all-cause hospitalization was also
sustained at 12 months (HR: 0.77; 95% CI: 0.70 to 0.86;
p < 0.001), as were the reductions in total costs
compared with the pre-implant interval (Table 2).
DISCUSSION
This analysis of publicly available data reﬂecting
clinical utilization of implantable hemodynamic
monitoring in Medicare patients during the commer-
cial period post-FDA approval suggest that the
reductions in HFH and cost savings seen in trial pop-
ulations may also be achievable in clinical practice.
The 45% lower rate of cumulative HFH observed at 6
months after PAP sensor implant versus the 6 months
prior to implantation compares favorably with the 28%
reduction seenwith PAP-guided therapy over the same
time period in the randomized CHAMPION study that
supported the initial FDA approval. Moreover, the
smaller cohort with 1-year pre- and post-implant data
suggest that, as in the trial, these beneﬁts may be du-
rable over longer-term follow-up, with a 34% reduc-
tion in HFH sustained at 12 months. Concomitant
reductions observed in all-cause hospitalization
following device implantation suggest that reduced
HFHs were not balanced by an increase in non–HF-
related events. Overall reductions in health care
utilization in the post-implant period translated into
substantial cost reductions at both 6 months and at
1 year compared with the pre-implant interval. These
data, which are robust in competing risk models and in
sensitivity analyses restricted to survivors as well as
ambulatory implants, provide “real-world evidence”
in an unselected population supporting the incre-
mental value of this approach to HF management.
Although randomized clinical trials remain the gold
standard for regulatory approval, regulatory agencies
have increasingly acknowledged that real-world data
may be used to generate valid scientiﬁc evidence
regarding device safety and effectiveness in a wider
patient population than that enrolled in a traditional
clinical trial (23). Accordingly, FDA approval of the PAP
sensor system was linked to the requirement to
conduct a formal post-marketing study to demonstrate
that the results achieved in the CHAMPION trial could
be replicated during commercial use. Pending the re-
sults of the post-approval study (NCT02279888), these
retrospective data from the Medicare population pro-
vide supportive data suggesting that the beneﬁts of
ambulatory hemodynamic monitoring seen in clinical
trials may be generalizable to a broader clinical context
(24). Important caveats to this analysis include the
absence of Part D Medicare claims data, which pre-
cludes a detailed analysis of medication changes
following device implantation, as well as the lack of
linked PAP sensor data, which makes it challenging to
conﬁrm that physicians intervened to treat elevated
PAPs. Accordingly, we are unable to deﬁnitively
ascertain whether reduced HFH rates are related to
undertreatment in the pre-implant period or improved
TABLE 2 Clinical Outcomes and Health Care Costs Before and After PAP Sensor Implantation for the 6- and 12-Month Cohorts
6-Month Cohort
(n ¼ 1,114)
12-Month Cohort
(n ¼ 480)
Pre-Implant Post-Implant Pre-Implant Post-Implant
Follow-up, patient-yrs 557 513 480 413
All-cause hospitalizations 1,899 1,119 1,387 859
HF-related 1,020 381 696 300
Non–HF-related 879 738 691 559
Days alive and out of hospital, % 93.9% 95.6% 94.8% 95.7%
VAD/Transplant 0 17 0 15
Deaths 0 139 0 106
Costs*
HF-related $12,410
($12,050 to $12,800)
$4,945
($4,633 to $5,300)
$19,900
($19,210 to $20,720)
$8,690
($8,057 to $9,291)
D cost (post  pre) $7,433 ($7,000 to $7,884) $11,260 ($10,460 to $12,020)
All-cause $28,870
($28,240 to $29,440)
$18,360
($17,710 to $18,970)
$47,690
($46,370 to $48,910)
$34,500
($33,110 to $36,000)
D cost (post  pre) $10,510 ($9,703 to $11,330) $13,190 ($11,590 to $14,740)
Values are n unless otherwise indicated. *Costs shown are per-patient/6 months for the 6-month cohort and per patient-yr for the 12-month cohort, along with IQR
(in parenthesis).
D ¼ change; HF ¼ heart failure; PAP ¼ pulmonary artery pressure; VAD ¼ ventricular assist device.
J A C C V O L . 6 9 , N O . 1 9 , 2 0 1 7 Desai et al.
M A Y 1 6 , 2 0 1 7 : 2 3 5 7 – 6 5 HFH Reductions With PAP Monitoring
2361
Downloaded for Anonymous User (n/a) at CentraCare Health from ClinicalKey.com by Elsevier on October 30, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
treatment in the post-implant period. Related data
from the ﬁrst 2,000 commercial PAP sensor implants
(including both Medicare and non-Medicare patients)
do suggest that PA pressure reductions achieved in
clinical practice are even greater than those seen in the
pivotal CHAMPION trial (17), and changes in PAP appear
to be tightly linked to clinical outcomes (25). Overall,
therefore, it seems reasonable to infer that the reduc-
tion in HFH is, in at least some measure, related to ac-
tion taken by clinicians in response to PAP sensor data.
Despite FDA approval, there has been an ongoing
dispute regarding the efﬁcacy of hemodynamic
monitoring, principally due to concerns regarding the
design of the pivotal trial (26). As well, during the
initial FDA review of the CHAMPION data, concerns
were raised about a possible variation in the beneﬁt of
hemodynamic monitoring according to sex, as
women in the treatment arm had a numerically
greater (but statistically nonsigniﬁcant) rate of HFH
than those in the control arm (27). The Medicare
cohort sampled for this study is nearly 4 the size of
the CHAMPION trial treatment arm, and includes a
larger proportion of women (40% vs. 23%) and elderly
subjects (mean age 71 years vs. 61 years; 40% over
75 years of age). Data from this broader patient sam-
ple reinforce the CHAMPION results by highlighting a
numerically greater reduction in HF hospitalizations
at 6 months than that seen in the trial, and provide
reassurance that these beneﬁts are consistent across
key subgroups of interest.
Although this is not a formal cost-effectiveness
analysis, these data regarding device utilization in
the commercial setting do provide some important
assurances regarding the economic implications of
ambulatory hemodynamicmonitoring. First, observed
rates of device utilization in the Medicare population
are far lower than those that drove early projections of
the potentially large budgetary effect of device
approval (28). Second, the observed reduction in
hospitalizations following device implantation is
CENTRAL ILLUSTRATION Cumulative HFHs During the Period Before and After Pulmonary Artery Pressure
Sensor Implantation
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0Post-implant:
Pre-implant:
1mo 2mo 3mo 4mo 5mo 6mo
1114 1114 1114 1114 1114 1114 1114
1114Post-implant
Pre-implant
Number at risk
1080 1049 1019 1002 976 955
0 -2mo -4mo -6mo -8mo -10mo -12mo
0Post-implant:
Pre-implant:
2mo 4mo 6mo 8mo 10mo 12mo
480 480 480 480 480 480 480
480Post-implant
Pre-implant
Number at risk
450 435 409 394 373 357
A B
Pre-implant HFH Post-implant HFH
Desai, A.S. et al. J Am Coll Cardiol. 2017;69(19):2357–65.
(A) 6-month cohort. (B) 12-month cohort. Hazard ratios were derived using the Andersen-Gill extension of the Cox proportional hazards model, accounting for the
competing risk of death, ventricular assist device, or transplant. Note that event accumulation during the pre-implant interval is counted backward from the time of
implant. Data highlight signiﬁcant reductions in cumulative HFHs in the period after device implantation compared with the period before implantation for both the
6- and 12-month cohorts. CI ¼ conﬁdence interval; HF ¼ heart failure; HFH ¼ heart failure hospitalization; HR ¼ hazard ratio.
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numerically higher than that seen in the trial, sup-
porting even greater cost reductions during the post-
implant interval than projected from the CHAMPION
data alone. Finally, the observation of sustained HFH
and cost reductions out to 1 year in a real-world pop-
ulation supports the notion that the beneﬁts of
hemodynamicmonitoringmay be durable over longer-
term follow-up, a factor that is essential for long-term
cost-effectiveness. Based on an average Medicare
reimbursement of $23,122  $16,891 for device
implantation in this cohort, the reduction of $13,190/
patient in comprehensive health care costs among
survivors over 1 year suggests a break-even point of
roughly 2 years to recoup the initial investment.
STUDY LIMITATIONS. First, these analyses were
derived from Medicare claims data, and accordingly
we are unable to provide details regarding medical
history, ejection fraction, the indication for PAP sensor
implantation, quality of life, device safety, and the
like. An objective method of identifying HFH per CMS
methodology was used for this claims dataset, and
there was no formal clinical event adjudication. Only
Medicare charges were incorporated in the cost
analyses, and accordingly, we are unable to account
for the personnel costs associated with remote
management. As this was a cohort-based comparison
of outcomes before and after device implantation, not
a prospective randomized study, we cannot exclude
the possibility that selection bias or enhancements of
HF disease management in the period after device
implant may also have confounded our results. How-
ever, because all patients had previously been hospi-
talized for HF, and because all implanting centers were
selected for their experience in HF management, it is
likely that background medical therapy did not differ
markedly in the periods before and after implantation.
Moreover, because HF is a progressive disease, with
rates of hospitalization accelerating with progression
toward the end stage, these results likely reﬂect a
conservative estimate of the reductions in worsening
HF, health care utilization, and cost that are likely to
be seen with ambulatory hemodynamic monitoring in
practice. Although censoring at the time of death,
VAD, and transplant introduces the potential for sur-
vivor bias, consistent reductions in HFH in models
accounting for competing risks, as well as sensitivity
analyses restricted to patients at risk for the full
duration of follow-up (6 or 12 months), suggest that
this bias did not meaningfully inﬂuence the results.
FIGURE 2 HFHs in Subgroups of Interest During Period Before and After PAP Sensor Implant (6-Month Cohort)
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Results for each subgroup reported as hazard ratios with 95% conﬁdence intervals, adjusted for competing risk of death, VAD, or
transplantation. These data demonstrate consistent reductions in HFHs in subgroups deﬁned by age and sex, as well as in cohorts excluding
post-implant deaths as well as post-implant death/VAD/transplant (to address potential survivor bias). HFH ¼ heart failure hospitalization;
PAP ¼ pulmonary artery pressure; VAD ¼ ventricular assist device.
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CONCLUSIONS
These data from the “real-world” experience of
Medicare implants of PAP sensors during the period
following device approval suggest that the use of
ambulatory hemodynamic monitoring is associated
with reductions in HFH and overall costs associated
with HF care. In tandem with data suggesting
effective reductions in PAPs among general-use pa-
tients who had the PAP sensor system implanted
since FDA approval (17), these observations support
the generalizability of the CHAMPION trial results to
clinical practice and argue for clinical effectiveness
of ambulatory hemodynamic monitoring as a strat-
egy for HF management.
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